aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
CTI Life Sciences Fund is a Canadian venture capital firm that specializes in start-up and seed stage investments, with a particular focus on the life sciences sector. The firm typically participates in Series A funding rounds, providing crucial early-stage capital to innovative companies in the biotechnology and pharmaceutical industries.
Notable portfolio companies include Somnus Therapeutics, which has raised $15 million, and XTuit Pharmaceuticals, which has raised $22 million. CTI Life Sciences Fund is known for its experienced team of key partners and decision-makers who bring a wealth of industry knowledge and strategic guidance to their portfolio companies. The firm also offers unique value-add services such as operational support and strategic partnerships to help their investments succeed.
Also Known As
CTI Life Sciences Fund
Operating Status
Active
CTI Life Sciences Fund Address
Montréal,
h3b 4m6
Canada
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts